124_pAAV-ProC3-CatCh-GFP-WPRE Citations (2)

Originally described in: Targeting neuronal and glial cell types with synthetic promoter AAVs in mice, non-human primates and humans.
Juttner J, Szabo A, Gross-Scherf B, Morikawa RK, Rompani SB, Hantz P, Szikra T, Esposti F, Cowan CS, Bharioke A, Patino-Alvarez CP, Keles O, Kusnyerik A, Azoulay T, Hartl D, Krebs AR, Schubeler D, Hajdu RI, Lukats A, Nemeth J, Nagy ZZ, Wu KC, Wu RH, Xiang L, Fang XL, Jin ZB, Goldblum D, Hasler PW, Scholl HPN, Krol J, Roska B Nat Neurosci. 2019 Jul 8. pii: 10.1038/s41593-019-0431-2. doi: 10.1038/s41593-019-0431-2. PubMed Journal

---

Articles Citing 124_pAAV-ProC3-CatCh-GFP-WPRE

Articles
Expression of NMNAT1 in the photoreceptors is sufficient to prevent NMNAT1-associated retinal degeneration. Brown EE, Scandura MJ, Pierce EA. Mol Ther Methods Clin Dev. 2023 Apr 18;29:319-328. doi: 10.1016/j.omtm.2023.04.003. eCollection 2023 Jun 8. PubMed
The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC. Oh SY, Park S, Lee S, Lee EJ, Kim TH, Choi SJ, Park SY, Kim JH, Lim SM, Lee JB, Cho BC, Hong MH, Yun MR. Cell Rep Med. 2025 Feb 18;6(2):101929. doi: 10.1016/j.xcrm.2025.101929. Epub 2025 Jan 27. PubMed

If you have published an article using this material, please email us at to have your article added to this page.